Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4998 USD | +1.07% | +2.00% | -23.11% |
Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
Mar. 25 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.11% | 2.16M | |
+41.79% | 54.04B | |
+47.02% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement